Copy number variations of CCL3L1 and long-term prognosis of HIV-1 infection in asymptomatic HIV-infected Japanese with hemophilia.
We set up a cohort of HIV-infected, asymptomatic Japanese patients with hemophilia for follow-up study in 1995. All subjects who had been infected with HIV-1 for more than 10 years met the criteria for long-term nonprogressors (LTNPs) at the time of entry; however, some of them later developed lymphopenia and required antiretroviral treatment during five more years of observation. In this study, we investigated the impacts of the CCL3L1 dose on the long-term prognosis in the subjects with chronic HIV-1 infection. We collected genomic DNA from 95 long-term survivors including 48 nonprogressors and 47 subjects receiving antiretroviral treatment. The distributions of CCL3L1 copy number significantly differed between the 95 HIV-1-infected subjects with hemophilia and 205 controls. Average copy number of CCL3L1 in the HIV-1-infected subjects was significantly lower than in control (5.00 +/- 0.22 vs 3.35 +/- 0.24, p < 0.001). Moreover, the subjects possessing two or less copies of CCL3L1 had significantly higher risk of acquiring HIV-1. However, CCL3L1 copy number variations had no significant effect on the disease progression among the LTNP subjects who had been afflicted with chronic HIV-1 infection for more than 15 years, when compared between nonprogressors and patients under treatment (3.68 +/- 0.37 vs 3.02 +/- 0.29, ns). Furthermore, variations in the CCL3L1 copy number had little effect on the levels of HIV-1 load among them. We conclude that variation in the CCL3L1 copy number is apparently not a factor that determines the prognosis of chronic HIV-1 infection, even though it is linked to HIV-1 susceptibility.
Nakajima
Toshiaki
T
Department of Molecular Pathogenesis, Medical Research Institute, Tokyo Medical and Dental University, Tokyo 101-0062, Japan.
Ohtani
Hitoshi
H
Naruse
Taeko
T
Shibata
Hiroki
H
Mimaya
Jun-Ich
JI
Terunuma
Hiroshi
H
Kimura
Akinori
A
D023241:Antiretroviral Therapy, Highly Active; D044466:Asian People; D019742:Chemokines, CC / Q000235:genetics*; D015331:Cohort Studies; D018450:Disease Progression; D005500:Follow-Up Studies; D018628:Gene Dosage; D020022:Genetic Predisposition to Disease; D014644:Genetic Variation; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy / Q000235:genetics* / Q000503:physiopathology*; D020276:HIV Long-Term Survivors; D015497:HIV-1; D006467:Hemophilia A / Q000150:complications*; D006801:Humans; D007564:Japan; D011379:Prognosis
C492767:CCL3L1 protein, human; D019742:Chemokines, CC